Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway

Chen,Jun; Hu,Xiao‑Yong

doi:10.3892/ol.2018.9310

Inhibition of histamine receptor H3R suppresses prostate cancer growth, invasion and increases apoptosis via the AR pathway

Authors:
- Jun Chen
- Xiao‑Yong Hu
View Affiliations

Affiliations: Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, P.R. China
Published online on: August 16, 2018 https://doi.org/10.3892/ol.2018.9310
Pages: 4921-4928
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Histamine h3 receptor (H3R) is expressed in numerous types of tumor and is associated with tumor cell proliferation, migration and invasion. However, whether H3R is expressed in prostate cancer remains unknown. Therefore, the expression and function of H3R in prostate cancer was investigated. Immunohistochemistry, reverse transcription‑quantitative polymerase chain reaction and western blotting all indicated overexpression of H3R in prostate cancer. Cell counting kit‑8 (CCK‑8), migration and invasion assays demonstrated that overexpressed H3R is associated with cell proliferation, migration and invasion. Inhibition of H3R induced cell apoptosis, however, androgen receptor protein expression was decreased. Overall, the results suggest that H3R is overexpressed in prostate cancer and associated with cell proliferation, migration and invasion. These results may broaden our understanding of the underlying pathological mechanisms of prostate cancer and aid the discovery of novel treatments for prostate cancer. These findings suggest that inhibition of H3R may have favorable application prospects in the treatment of prostate cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A6, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Graff RE, Meisner A, Ahearn TU, Fiorentino M, Loda M, Giovannucci EL, Mucci LA and Pettersson A: Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by ERG tumour protein expression. Br J Cancer. 114:939–944. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, et al: EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, metastatic and castration-resistant prostate cancer. Eur Urol. 71:630–642. 2017. View Article : Google Scholar : PubMed/NCBI
5	James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, et al: Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 377:338–351. 2017. View Article : Google Scholar : PubMed/NCBI
6	Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, et al: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 373:737–746. 2015. View Article : Google Scholar : PubMed/NCBI
7	Sammon JD, Abdollah F, Reznor G, Pucheril D, Choueiri TK, Hu JC, Kim SP, Schmid M, Sood A, Sun M, et al: Patterns of declining use and the adverse effect of primary androgen deprivation on all-cause mortality in elderly men with prostate cancer. Eur Urol. 68:32–39. 2015. View Article : Google Scholar : PubMed/NCBI
8	Armitage JO and Sidner RD: Antitumour effect of cimetidine. Lancet. 1:882–883. 1979. View Article : Google Scholar : PubMed/NCBI
9	Wang WT, Chen YH, Hsu JL, Leu WJ, Yu CC, Chan SH, Ho YF, Hsu LC and Guh JH: Terfenadine induces anti-proliferative and apoptotic activities in human hormone-refractory prostate cancer through histamine receptor-independent Mcl-1 cleavage and Bak up-regulation. Naunyn Schmiedebergs Arch Pharmacol. 387:33–45. 2014. View Article : Google Scholar : PubMed/NCBI
10	Blaya B, Nicolau-Galmés F, Jangi SM, Ortega-Martínez I, Alonso-Tejerina E, Burgos-Bretones J, Pérez-Yarza G, Asumendi A and Boyano MD: Histamine and histamine receptor antagonists in cancer biology. Inflamm Allergy Drug Targets. 9:146–157. 2010. View Article : Google Scholar : PubMed/NCBI
11	Zheng Y, Xu M, Li X, Jia J, Fan K and Lai G: Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol Immunol. 54:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
12	Tanaka S, Sakaguchi M, Yoneyama H, Usami Y and Harusawa S: Histamine H3 receptor antagonist OUP-186 attenuates the proliferation of cultured human breast cancer cell lines. Biochem Biophys Res Commun. 480:479–485. 2016. View Article : Google Scholar : PubMed/NCBI
13	Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C, Zhang Z, Xu YQ, Chang T and Li ZY: Inhibition of histamine receptor 3 suppresses glioblastoma tumor growth, invasion, and epithelial-to-mesenchymal transition. Oncotarget. 6:17107–17120. 2015.PubMed/NCBI
14	Donoso AO and Banzan AM: H1- and H2-histamine receptor antagonists and induced release of prolactin in male rats. Neuroendocrinology. 30:11–14. 1980. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM and Xiang J: Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res. 17:531–536. 2007. View Article : Google Scholar : PubMed/NCBI
17	Liu C, Lou W, Armstrong C, Zhu Y, Evans CP and Gao AC: Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition. Prostate. 75:1341–1353. 2015. View Article : Google Scholar : PubMed/NCBI
18	Barber AG, Castillo-Martin M, Bonal DM, Jia AJ, Rybicki BA, Christiano AM and Cordon-Cardo C: PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Cancer Med. 4:1258–1271. 2015. View Article : Google Scholar : PubMed/NCBI
19	Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S and De Marzo AM: MYC and prostate cancer. Genes Cancer. 1:617–628. 2010. View Article : Google Scholar : PubMed/NCBI
20	Gray IC, Stewart LM, Phillips SM, Hamilton JA, Gray NE, Watson GJ, Spurr NK and Snary D: Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer. 78:1296–1300. 1998. View Article : Google Scholar : PubMed/NCBI
21	Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, et al: Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): A randomised, controlled, double-blind, crossover trial. Lancet. 390:2481–2489. 2017. View Article : Google Scholar : PubMed/NCBI
22	Rossing MA, Scholes D, Cushing-Haugen KL and Voigt LF: Cimetidine use and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 9:319–323. 2000.PubMed/NCBI
23	Ragnarsson O, Johannsson G, Geterud K, Lodding P and Dahlqvist P: Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer. BMJ Case Rep. 2013:pii: bcr20130103952013. View Article : Google Scholar
24	Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
25	Yeap BB, Krueger RG and Leedman PJ: Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology. 140:3282–3291. 1999. View Article : Google Scholar : PubMed/NCBI
26	Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A, Li J, Qi Y, Silberstein J, Lee B, et al: A whole blood assay for AR-V7 and ARv567es in patients with prostate cancer. J Urol. 196:1758–1763. 2016. View Article : Google Scholar : PubMed/NCBI
27	Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C and Balk SP: Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res. 20:1590–1600. 2014. View Article : Google Scholar : PubMed/NCBI
28	Sharma NL, Massie CE, Ramos-Montoya A, Zecchini V, Scott HE, Lamb AD, MacArthur S, Stark R, Warren AY, Mills IG and Neal DE: The androgen receptor induces a distinct transcriptional program in castration-resistant prostate cancer in man. Cancer Cell. 23:35–47. 2013. View Article : Google Scholar : PubMed/NCBI
29	Mills IG: Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nat Rev Cancer. 14:187–198. 2014. View Article : Google Scholar : PubMed/NCBI
30	Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ and Sharifi N: Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature. 533:547–551. 2016. View Article : Google Scholar : PubMed/NCBI
31	Pfanzagl B, Mechtcheriakova D, Meshcheryakova A, Aberle SW, Pfragner R and Jensen-Jarolim E: Activation of the ileal neuroendocrine tumor cell line P-STS by acetylcholine is amplified by histamine: Role of H3R and H4R. Sci Rep. 7:13132017. View Article : Google Scholar : PubMed/NCBI
32	Davenas E, Rouleau A, Morisset S and Arrang JM: Autoregulation of McA-RH7777 hepatoma cell proliferation by histamine H3 receptors. J Pharmacol Exp Ther. 326:406–413. 2008. View Article : Google Scholar : PubMed/NCBI
33	Medina V, Croci M, Crescenti E, Mohamad N, Sanchez-Jiménez F, Massari N, Nuñez M, Cricco G, Martin G, Bergoc R and Rivera E: The role of histamine in human mammary carcinogenesis: H3 and H4 receptors as potential therapeutic targets for breast cancer treatment. Cancer Biol Ther. 7:28–35. 2008. View Article : Google Scholar : PubMed/NCBI